Saturday, August 10, 2013 6:17:15 PM
Operator
Good afternoon ladies and gentlemen, I would like to welcome you to the epigenomics half-year, 2013,
financial results and operational update conference call. At this time, all participants have been placed
on a listen-only mode. The floor will be open for questions following the presentation. I would now like
to turn the call over to Thomas Taapken, CEO and CFO at Epigenomics. You may begin your conference
call.
www.epigenomics.com/fileadmin/site_files/00_NEWS/20_investor_relations/20_finance_information/2013/Transcript_Conference_Call_August_7__2013.pdf
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM